CD79A and thrombotic disease: A similar result was obtained in a study focusing on the prevalence of thrombotic complications in a larger cohort of 122 patients, 16 of whom had severe thrombotic complications; anti-β2GPI IgG/IgA/IgM were at 15.6/6.6/9.0%, and aCL IgG/IgM at 5.7/6.6%; no relationship to thromboses could be observed [19].